Login to Your Account


Search results

Pharma: Clinic Roundup

• Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, reported Phase II data showing that TAK-875, a GPR40 agonist, met its primary endpoint of statistically significantly lowering HbA1c levels over a 12-week period vs. placebo in Type II diabete ...

BioWorld Today - Staff - 2012-02-28 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Grupo Ferrer International SA , of Barcelona, Spain, said lorediplon was well tolerated and demonstrated efficacy comparable to or in excess of Ambien (zolpidem, Sanofi SA) in a Phase I insomnia trial. (BioWorld-Today-2012-02-10) ...

BioWorld Today - Staff - 2012-02-10 01:00 - 0 comments - 0 attachments